← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
Andreessen Marc L
10% Owner
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001160077
Purchase history
- Companies traded
- 3
- Purchases · 12M
- 6
- Purchases · 24M
- 6
- Average purchase
- $11.3M
- Median purchase
- $12.6M
- Gross purchase value
- $67.7M
Companies: Braveheart Bio, Inc. | Navan, Inc. | Scribe Therapeutics, Inc.
6 SEC accession(s) · 6 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-08-11 | Braveheart Bio, Inc. | BRVE | 10% Owner | $19.8M | Open filing |
| 2026-07-29 | Scribe Therapeutics, Inc. | SCTX | 10% Owner | $5.0M | Open filing |
| 2026-01-09 | Navan, Inc. | NAVN | 10% Owner | $839.2K | Open filing |
| 2026-01-06 | Navan, Inc. | NAVN | 10% Owner | $15.9M | Open filing |
| 2025-12-29 | Navan, Inc. | NAVN | 10% Owner | $16.7M | Open filing |
| 2025-12-19 | Navan, Inc. | NAVN | 10% Owner | $9.4M | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 2Small Sample | 33.3% (2/6) | 100.0% (2/2) | +15.7% | +15.7% | +7.4% |
| 20D | 2Small Sample | 33.3% (2/6) | 100.0% (2/2) | +42.1% | +42.1% | +16.7% |
| 60D | 0No Data | 0.0% (0/4) | — | — | — | — |
| 120D | 0No Data | 0.0% (0/4) | — | — | — | — |
Research patterns
- First purchase in 12M
- 3/6
- Large purchase ≥ $100k
- 6/6
- Cluster buying · 15D
- 6/6
- Buying the dip
- 0/—
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.